By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit, and

Key Statistics

Ownership: Public

Web Site: Genomic Health
Symbol: GHDX


Company News
Genomic Health (GHDX) Release: Oncotype DX Predicts 10-Year Risk Of Developing Metastatic Prostate Cancer In Low- And Intermediate-Risk Patients 3/29/2017 6:56:33 AM
Genomic Health (GHDX) Release: Published Outcomes Results From SEER Registries Indicates That Many Node-Positive Breast Cancer Patients Can Avoid Chemotherapy Based On Oncotype DX Results 3/24/2017 7:03:12 AM
Genomic Health (GHDX) Unveils A Wealth Of Data For The Oncotype DX Breast Cancer Test, Reinforcing Its Value In Improving Patient Outcomes And Leading To More Cost-Effective Management 3/17/2017 7:31:03 AM
Genomic Health (GHDX) Release: Four New Studies Of Oncotype DX Genomic Prostate Score (GPS) Reconfirm Value Of Test In Guiding Early-Stage Prostate Cancer Risk Assessment And Treatment Selection 2/16/2017 8:08:00 AM
Genomic Health (GHDX) Announces 2016 Fourth Quarter And Year-End Financial Results, Provides 2017 Financial Outlook 2/15/2017 8:12:35 AM
Genomic Health (GHDX) To Announce Fourth Quarter And Year-End 2016 Financial Results And Host Conference Call On Tuesday, February 14, 2017 2/7/2017 10:26:43 AM
Genomic Health (GHDX) Announces Inclusion Of Oncotype DX In The 8th Edition Of American Joint Committee On Cancer (AJCC) Criteria For Breast Cancer Staging 12/22/2016 12:41:19 PM
Genomic Health (GHDX) Announces Results From Multiple Oncotype DX Studies, Reinforcing Its Impact In Delivering Precision Medicine To Breast Cancer Patients Around The World 12/9/2016 8:22:48 AM
Genomic Health (GHDX) Reports Third Consecutive Quarter Of Double-Digit Revenue Growth In Announcement Of Third Quarter 2016 Financial Results 11/2/2016 8:13:53 AM
Genomic Health (GHDX) Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX Prostate Cancer Test Predicts Risk Of Metastasis And Mortality 11/2/2016 6:50:13 AM